Top section
Top section
‘New kid on the block’ disrupts established order with lead role on Schroders takeover
More articles
More articles
More articles
-
Chinese company Zhaoke Ophthalmology has kicked off a Hong Kong IPO worth up to HK$2.1bn ($270m), becoming the latest biotechnology company to sell shares on the bourse. -
US investment banks have set a high bar for their European rivals by posting record revenues powered by a boom in capital markets underwriting.
-
Equity and debt markets were fretting on Thursday over the implications of new US sanctions against Russia. A prohibition of US investment in Russian sovereign bonds marked an escalation in tensions, threatening sovereign borrowing costs. It could also damage Russian companies’ chances of funding in the capital markets, write Mariam Meskin and Sam Kerr.
-
The relentless flow of special purpose acquisition companies coming to the market is causing unease among investors about market saturation, with $140bn raised so far this year. Only the highest quality sponsors are likely to succeed in bringing new Spacs to IPO from now on, writes Aidan Gregory.
-
The Central Bank of the Republic of Turkey on Thursday held its key interest rate at 19% despite fears that new governor and low interest rate champion Şahap Kavcıoğlu would cut rates. But despite the policy move, investor anxieties remain.
-
A planned restructuring of China’s Ant Group into a financial holding company has raised questions — and fuelled speculation — about when the firm is able to revive its derailed IPO and how it will be valued. Addison Gong reports.
Sub-sections
shared comment list
